Infiltrations of plasma cells in synovium predict inadequate response to Adalimumab in Rheumatoid Arthritis patients.
Adalimumab
Rheumatoid arthritis
Synovial plasma cell infiltration
Treatment response
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
28
04
2024
accepted:
28
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) is a clinically heterogeneous and complex autoimmune disease, making the prediction of therapeutic responses a significant challenge. This study aims to assess the role of clinical and synovial biomarkers in predicting poor response to adalimumab treatment in RA patients. This single-center prospective study included 56 RA patients who had an inadequate response to methotrexate (MTX). At baseline, comprehensive assessments including complete blood count, liver and kidney function tests, blood glucose levels, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA), as well as counts of swollen and tender joints, Health Assessment Questionnaire (HAQ) score, pain visual analogue scale (VAS) scores, and DAS28-CRP scores were conducted. Synovial biopsies were performed, followed by an efficacy evaluation at 12 weeks of adalimumab treatment. Patients not meeting the ACR20 criteria were classified into the non-responder group, with the remainder categorized as the responder group. Out of the participants, 24 (42.9%) failed to achieve ACR20 with adalimumab treatment. Non-responders exhibited higher infiltration of plasma cells in the synovium. Multivariate logistic regression analysis identified the presence of plasma cells as an independent risk factor for inadequate response to adalimumab. Inadequate responses to adalimumab in RA patients were associated with increased plasma cell infiltrations in the synovium. These findings suggest a promising target for tailored therapies in rheumatoid arthritis.
Identifiants
pubmed: 39482773
doi: 10.1186/s13075-024-03426-2
pii: 10.1186/s13075-024-03426-2
doi:
Substances chimiques
Adalimumab
FYS6T7F842
Antirheumatic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
186Informations de copyright
© 2024. The Author(s).
Références
Shao Y, Zhang H, Shi Q, et al. Clinical prediction models of rheumatoid arthritis and its complications: focus on cardiovascular disease and interstitial lung disease. Arthritis Res Ther. 2023;25(1):159.
doi: 10.1186/s13075-023-03140-5
pubmed: 37658422
pmcid: 10472585
Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid arthritis: a brief overview of the treatment. Med Princ Pract. 2018;27(6):501–7.
doi: 10.1159/000493390
pubmed: 30173215
pmcid: 6422329
Pelechas E, Voulgari PV, Drosos AA. Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opin Drug Discov. 2021;16(3):227–34.
doi: 10.1080/17460441.2021.1846516
pubmed: 33183071
Tamai H, Ikeda K, Miyamoto T, et al. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial. Lancet Rheumatol. 2023;5(4):e215–24.
doi: 10.1016/S2665-9913(23)00070-X
pubmed: 38251524
Machado MA, Maciel AA, de Lemos LL et al. Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials. Rev Bras Reumatol. 2013 Sep-Oct;53(5):419 – 30. English, Portuguese. Erratum in: Rev Bras Reumatol. 2014 Mar-Apr;43(2):160.
Taylor PC, Matucci Cerinic M, Alten R, et al. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114101.
doi: 10.1177/1759720X221114101
pubmed: 35991524
pmcid: 9386864
Radner H, Neogi T, Smolen JS, et al. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2014;73(1):114–23. https://doi.org/10.1136/annrheumdis-2013-203284 .
Moelants EA, Mortier A, Van Damme J, et al. Regulation of TNF-α with a focus on rheumatoid arthritis. Immunol Cell Biol. 2013;91(6):393–401.
doi: 10.1038/icb.2013.15
pubmed: 23628802
Papagoras C, Voulgari PV, Drosos AA. Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatol. 2009;1:51–68.
pubmed: 27789981
pmcid: 5074727
Taylor PC, Matucci Cerinic M, et al. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114101.
doi: 10.1177/1759720X221114101
pubmed: 35991524
pmcid: 9386864
Khader Y, Beran A, Ghazaleh S, et al. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol. 2022;41(12):3615–27.
doi: 10.1007/s10067-022-06307-8
pubmed: 35974226
pmcid: 9652218
Yue X, Huang B, Hincapie AL, et al. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA. Rheumatology (Oxford). 2021;60(9):4063–73.
doi: 10.1093/rheumatology/keaa877
pubmed: 34469569
Hardt U, Carlberg K, Af Klint E, et al. Integrated single cell and spatial transcriptomics reveal autoreactive differentiated B cells in joints of early rheumatoid arthritis. Sci Rep. 2022;12(1):11876.
doi: 10.1038/s41598-022-15293-5
pubmed: 35831338
pmcid: 9279471
Dennis G Jr, Holweg CT, Kummerfeld SK, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16(2):R90.
doi: 10.1186/ar4555
pubmed: 25167216
pmcid: 4060385
Zhao J, Ye X, Zhang Z. The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs. Clin Rheumatol. 2020;39(9):2573–81.
doi: 10.1007/s10067-020-05043-1
pubmed: 32206975
Kanbe K, Chiba J, Nakamura A. Decrease of CD68 and MMP-3 expression in synovium by treatment of adalimumab for rheumatoid arthritis. Int J Rheum Dis. 2011;14(3):261–6.
doi: 10.1111/j.1756-185X.2011.01643.x
pubmed: 21816022
Humby F, Durez P, Buch MH, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397(10271):305–17.
doi: 10.1016/S0140-6736(20)32341-2
pubmed: 33485455
pmcid: 7829614
Allen HC, Sharma P, Histology PC. [Updated 2022 Dec 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK556082/
Karmakar U, Vermeren S. Crosstalk between B cells and neutrophils in rheumatoid arthritis. Immunology. 2021;164(4):689–700.
doi: 10.1111/imm.13412
pubmed: 34478165
pmcid: 8561113
Lewis MJ, Barnes MR, Blighe K, et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 2019;28(9):2455–e24705.
doi: 10.1016/j.celrep.2019.07.091
pubmed: 31461658
pmcid: 6718830
Dolzani P, Manferdini C, Meliconi R, et al. Preliminary study on immune cells in the synovium of end-stage osteoarthritis and rheumatoid arthritis patients: neutrophils and IgG4-secreting plasma cells as differential diagnosis candidates. Acta Histochem. 2022;124(5):151909.
doi: 10.1016/j.acthis.2022.151909
pubmed: 35679805
Dong W, Li X, Liu H, et al. Infiltrations of plasma cells in synovium are highly associated with synovial fluid levels of APRIL in inflamed peripheral joints of rheumatoid arthritis. Rheumatol Int. 2009;29(7):801–6.
doi: 10.1007/s00296-008-0773-7
pubmed: 19037609